In the Liraglutide Effects in Atrial Fibrillation (LEAF) Study, researchers at the University of Miami Miller School of Medicine, led by Jeffrey Goldberger, M.D., cardiac electrophysiologist and professor of cardiovascular medicine at the Miller School, found that adding the GLP1 receptor agonist liraglutide to a structured riskfactor modification program significantly improved freedom from AFib or atrial flutter one year after catheter ablation in overweight and obese patients
GLP-1 drugs work by mimicking the hormone and keeping it around longer, which can aid in appetite suppression
Adults need about 2.5 mg of this vitamin daily, for blood cell health and overall vitality
This product is not intended for: Human consumption Medical treatment Disease diagnosis Disease prevention Veterinary applications Therapeutic use Purchasers are responsible for ensuring compliance with all applicable laws, regulations, and institutional policies governing the acquisition, storage, handling, and use of research peptides
Pet parents focused on metabolic health and portion control
Call Maffi Plastic Surgery at 480.505.6430 or send an email consultation request today
